Introduction OrNAgade Joint Venture (JV) was established as a collaboration between two biotechnology companies, Orion Biotechnology Canada and Agalimmune Ltd, in 2021. The JV combines Orion's expertise in G protein-coupled receptor (GPCR)-targeting drugs and Agalimmune's immuno-oncology capabilities. With a shared vision of making revolutionary advancements in RNA therapeutics, they teamed up to leverage their combined assets, knowledge, and resources. Together, the Joint Venture endeavors to create next-generation RNA treatments powered by proprietary oRNATM technology. |